2 CIHIDECAR, Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón II, 1428 Buenos Aires, Argentina, and 3 Instituto de Investigaciones Biotecnológicas-Instituto Tecnológico de Chascomús, Universidad Nacional de General San Martín y Consejo Nacional de Investigaciones Cientificas y Tecnicas, INTI, Av. General Paz s/n, Edificio 24, Casilla de correo 30, 1650 General San Martín, Argentina
Received on February 6, 2004; revised on March 15, 2004; accepted on March 15, 2004
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: alternative substrates / HPAEC / inhibitors / trans-sialidase / Trypanosoma cruzi
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Given the essential roles of TcTS in infection and pathogenesis, this enzyme is a good target for the development of alternative chemotherapy against the parasite. Nevertheless, no specific inhibitor of TcTS is currently available. A sialidase inhibitor, analog to the oxocarbenium transition state of the reaction, 2,3-didehydro-2-deoxy-N-acetylneuraminic acid (Neu2en5Ac), has to be used 100 times more concentrated to inhibit TcTS when compared to bacterial and viral sialidases. The 3D structure of TcTS was recently determined and the catalytic mechanism elucidated (Amaya et al., 2003
; Buschiazzo et al., 2000
, 2002
). TcTS has two (sub)sites in the active center: the sialic acidbinding site and the galactose-binding site. The sialic acid (sub)site is present in all sialidases but in TcTS is somewhat different. The sugar enters in a tilted position compared with other sialidases, partially explaining the lack of inhibition observed with Neu2en5Ac. On the other hand, the lactose (sub)site is absent in all known sialidases and is formed on binding of substrate. Binding of the sialic acid moiety of the donor substrate in the TcTS reactive center triggers a conformational switch that creates the sugar acceptor-binding site for a terminal ß-galactose. In the free enzyme, the Tyr119 points toward the floor of the catalytic pocket filling the space of sialic acid. On binding of the donor substrate, the Tyr119 side chain suffers a displacement leaving the sialic acid binding cleft and forming a stacking interaction with lactose, which is placed against the Trp312. In addition to creating the acceptor-binding site, a second consequence of the binding of sialic acid is a conformational switch of a Tyr residue at position 342, which is the catalytic nucleophile making a covalent bond with the sialic acid intermediary state of the reaction (Watts et al., 2003
).
So far, the best donor and acceptor molecules known are sialic acid (2,3)-linked to a ß-galactose, and a terminal ß-galactose respectively (Scudder et al., 1993
; Vandekerckhove et al., 1992
). In vitro, 3'-sialyllactose and lactose are widely used to assay for TcTS activity. In vivo, 3'-sialyl N-acetyllactosamine structures are present in a number of mammalian glycoconjugates while terminal ß-galactosyl units are constituents of parasite mucins (Acosta-Serrano et al., 2001
). In the present study we tested lactose derivatives modified in the glucose constituent with the aim of understanding the contribution of the sugar linked to galactose in the trans-sialidase reaction. It was previously described (Buschiazzo et al., 2002
) that the 3-OH of the reducing glucose in lactose is involved in water-mediated hydrogen bonds with the enzyme. We found that lactitol is an excellent acceptor of sialic acid but sialyllactitol was unable to act as a donor substrate. Lactitol was able to inhibit the trans-sialidase reaction toward conventional substrates in vitro and to interfere with parasite infection in cultured cells. These results suggest that the lactose-binding site of TcTS might be used for the design of inhibitors to be tested against trypanosomal infections.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
The next question was if the chain length of the sugar linked to the ß-galactose substrate is important for TcTS activity. 3-O-ß-D-Galactopyranosyl-D-arabinose (GalAra, Figure 1) was tested as acceptor. When the substrate GalAra was analyzed by HPAEC using condition 5, the 3-O-ß-D-galactopyranosyl-D-arabinopyranoses (GalArap, tR 14.10) and the 3-O-ß-D-galactopyranosyl-D-arabinofuranoses (GalAraf, tR 40.40) were detected (tR of lactose 22.30, data not shown). The furanose structure for the reducing end was assigned for the disaccharides with the highest retention time because we have previously shown that isomeric furanose disaccharides are retained for longer times on HPAEC (Salto et al., 2000). On the other hand, the ratio of pyranoses to furanoses is in agreement with the integration for the anomeric centers in the nuclear magnetic resonance (NMR) spectra (Othegui et al., 1990
). HPAEC conditions were optimized using a CarboPac PA-10 column that provides better resolution for compounds with the same molecular weight.
When GalAra was incubated with 3'-sialyllactose and trans-sialidase, two sialylated products were observed corresponding to the saccharides with the arabinopyranose and the arabinofuranose at the reducing end respectively (42% total transference, Figure 2E). Considering that the presence of an arabinose residue instead of glucose did not prevent trans-sialylation, it was interesting to investigate if the same happened when arabinitol was present instead of glucitol, the constituent of lactitol. 3-O-ß-D-galactopyranosyl-D-arabinitol (GalAraol, Figure 1) was prepared by reduction of GalAra with NaBH4. The corresponding alditol was characterized by 13C-NMR that showed only one anomeric carbon at 103.8 ppm and three primary carbons at 63.01 ppm, 61.82 ppm, and 60.41 ppm. Figure 2D shows that GalAraol is also a good acceptor in the trans-sialidase reaction (74% transference). In fact, the alditol was a better acceptor than the disaccharide GalAra. These results indicate that the length of the carbon chain of the residue to which the galactose is ß-linked is not restricted to six carbon atoms for the reaction to take place.
Another lactose derivative with its C-1 modified with a tetrazole residue, was also tested as a substrate for TcTS. Lactotetrazole (Figure 1) was obtained by treatment of the perbenzoylated compound (Othegui et al., 1990) with sodium methoxide in methanol. Although tetrazole is a weak acid similar in strength to acetic acid (pKa = 4.76), under the conditions used, lactotetrazole was eluted in the region of the neutral lactose derivatives (tR 2.60 min, lactose tR 3.20 min, condition 4). Presence of a sialylated lactotetrazole was not detected (data not shown).
Different extent of sialic acid transfer was observed with the acceptor substrates used. Therefore, we estimated the apparent Km for each acceptor to quantify the relative affinity of TcTS for the substrates (Figure 3). The rate of the enzymatic reaction with respect to the different substrates was expressed as the percentage of sialylated substrate synthesized over a period of 15 min. Incubations were carried out with 1 mM 3'-sialyllactose, 40 ng trans-sialidase and different substrate concentrations. As can be observed in Figure 3, lactitol has the lowest Km value (0.26 mM). The value obtained for N-acetyllactosamine was in the range of that for lactose (Ribeirao et al., 1997). Lactobionic acid and the alditol GalAraol seem to be poorer acceptors having Km values four to six times larger than that of lactitol. The Km of the disaccharide GalAra was not determined because the presence of the two configurations in the arabinose residue did not allow an accurate measurement.
|
Sialyllactobionic acid was also prepared by using fetuin as the donor of sialic acid as described under Materials and methods. When sialylated lactobionic acid was used as donor, it was completely consumed, deriving in the formation of sialyllactose and lactobionic acid (Figure 4B). In contrast, when sialyllactitol was used as donor, sialylation of lactose was not observed at any of the concentrations of sialyllactitol used, although the presence of the donor could clearly be observed in the chromatograms (Figure 4A). An intermediate situation was found when sialyllactosamine was used as the donor. Figure 4C shows the presence of both compounds, sialylated lactose, and the remaining sialyllactosamine. These results correlated with the appKm values obtained. The worse a compound behaved as an acceptor in the trans-sialidase reaction, the better its sialylated derivative behaved as a donor in the reverse reaction. In the case of sialyllactitol, the absence of transference when lactose is used as an acceptor suggests that lactitol is preferably sialylated instead of lactose and that once the sialyllactitol is formed, the reaction cannot be forced backward.
|
|
|
|
Lactitol inhibited parasite sialylation in vivo
The in vivo effect of lactitol on mucin resialylation by TcTS was analyzed measuring the total sialic acid content of parasites. Bovine serum albumin (BSA)parasites were collected in serum-free medium with BSA. In this medium, parasite sialylation is prevented due to the absence of sialic acid donors. Total sialic acid content was determined by the thiobarbituric acid method with high-performance liquid chromatography (HPLC) analysis in BSA-parasites and in parasites that were resialylated with recombinant TcTS and sialyllactose as donor. Both conditions were performed in the absence or presence of lactitol (see Materials and methods for further details). Three independent experiments for each of the conditions were done (Table II).
|
Effect of lactitol in the infection of culture mammalian cells by T. cruzi
Sialic acid was suggested to influence the infection of host cells by the parasite. Thus the identification of acceptor molecules that efficiently compete with N-acetyllactosamine for the sialic acid transferred by TcTS prompted us to test their effect in a culture cell infection assay. BSA-parasites (see previous discussion) were incubated with Vero cells; after 3 days, the number of infected cells were counted (see Materials and methods for details). On contact with Vero cells, parasites might incorporate sialic acid from the glycoconjugates present on the surface of the host cells. In this step lactitol might prevent parasite sialylation and thus prevent cell infection. Under a second condition, BSA-parasites were resialylated with TcTS and sialyllactose before used to infect Vero cells. Presence of lactitol was maintained through all the procedure.
Under the two conditions, BSA-parasites and BSA-parasites resialylated with TcTS, lactitol was able to inhibit infection to a similar extent (2027% of inhibition, Table III). The experiments were repeated three to seven times (see Table III), and the differences observed between control and lactitol-treated groups were statistically significant (p = 0.001). No morphological alterations in both, parasites and Vero cells, were observed throughout the experiments under any of the conditions used. As a control, parasites collected in BSA were incubated with lactose at the same concentration used for lactitol. No effect on the infection by T. cruzi was observed with lactose (Table III).
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Previous crystallographic studies showed that the OH-3 of the glucose in lactose is involved in water-mediated hydrogen bonding with Arg311 (Buschiazzo et al., 2002). We found that the reducing sugar might be also replaced by an alditol. More important, lactitol is the preferred acceptor in the presence of lactose/N-acetyllactosamine, further supporting the idea that the open chain in fact favors the transfer reaction. Similar results have been obtained with T. congolense trans-sialidase using lactitol as acceptor in a competitive assay with 2'-(4-methylumbelliferyl) galactoside (MUGal) (Tiralongo et al., 2003
). Thus the alditol would be more flexible for adopting a conformation that favors hydrogen bond interactions with the enzyme. Also the alditol GalAraol was more efficient than GalAra for preventing sialylation of N-acetyllactosamine. The fact that no free sialic acid was observed with lactitol as acceptor indicates that the sialic acid is efficiently transferred, instead of being hydrolyzed. So far, free sialic acid was always observed with all other acceptor molecules tested, indicating that although TcTS is a very efficient transferase, some hydrolytic activity was detectable. This was not the case with lactitol as acceptor, or at least not at the level of detection used. When sialyllactitol was used as donor, no transfer to N-acetyllactosamine could be detected (Figure 4A). A probable explanation of this result is that the sialic acid is rapidly transferred backward to lactitol from the acceptor substrate because TcTS has a higher affinity for lactitol than for N-aceyllactosamine.
TcTS 3D structure revealed the existence of two (sub)sites within the catalytic region of the enzyme (Buschiazzo et al., 2002). One is involved in binding sialic acid present in the donor molecule. This site proved to be somewhat different to that of other sialidases. Some of the amino acid residues present in TcTS make the sialic acid ring enter in a tilted position as compared with TrSA. Whether these, and other structural differences (see Buschiazzo et al., 2002
) are enough for the design of specific TcTS inhibitors directed to the sialic acidbinding site, remains to be studied. A 2,3 difluor derivative of sialic acid used to identify a covalent sialyl-enzyme intermediate was found to inactivate wild-type TcTS, although high concentrations (20 mM) were necessary for complete inactivation (Watts et al., 2003
). In the present work, the second (sub)site of the enzyme was analyzed as a possible target of TcTS inhibitors. This site binds the terminal galactose accepting the transferred sialic acid and involves a groove between Trp312 and Tyr119 that is present in trans-sialidases but not in sialidases.
Lactitol is so far the first example of a compound other than antibodies (Leguizamon et al., 1994; Pitcovsky et al., 2002
) able to inhibit TcTS reaction toward substrates like lactose/N-acetyllactosamine. Interestingly, the galactose target site is only formed on binding of the sialic acid donor. Thus we assume that once the donor of sialic acid is bound to the active site and the site for the galactose is formed, lactitol is able to successfully compete with other acceptors in the medium. In fact, it is able to compete with lactose/N-acetyllactosamine, which are widely used as acceptors to test for biochemical TS activity in vitro. Interestingly, and as predicted from the in vitro inhibition experiments, lactitol is able to prevent parasite sialylation in culture medium (Table II). In accordance, lactitol has also an effect on the infection of mammalian cells (Table III), as expected from previous results (Schenkman et al., 1993
) indicating that sialic acid on the parasite surface is required for this purpose. Nevertheless, the decrease in cell infection, 2027% compared to control, is far from complete. Because parasite desialylation is not complete, the sialic acid remaining on its surface might be enough for parasites to invade the host cell. This is also in accordance with previous results showing that partially desialylated parasites were still able to invade mammalian cells (Schenkman et al., 1991
, 1993
). It is relevant to point out that a large number of parasites has to be used in the invasion experiments (200:1 trypanosomes:cultured mammalian cells) to obtain a number of infected cells amenable for quantification. These conditions are not comparable to those in nature, in which a few parasites deposited on the skin with the feces of the insect vector are enough to infect a human being.
Presently the best alternative to control Chagas' disease is to prevent the infection. This is done by controlling the triatomines and by testing for T. cruzi presence in blood used for transfusions. Once humans are infected, there are two products that are effective (albeit toxic) during the acute phase of the infection: nifurtimox and benznidazole (Cerecetto and Gonzalez, 2002). The effectiveness of these chemicals during the chronic phase of the infection is still under discussion (Kirchhoff, 2003
; Urbina and Docampo, 2003
). Thus finding new targets for chemotherapy of T. cruzi infection is needed. Trans-sialidase, a virulence factor that induces apoptosis in cells from the immune system (Leguizamon et al., 1999
; Mucci et al., 2002
), is a good alternative for the design of inhibitors. In this context, lactitol is a very innocuous molecule with an LD50 of about 10 g/kg weight in mice (Okazaki et al., 1994
). However, lactitol is a small molecule, being quickly eliminated from blood. Our results provoke further investigations on the design and testing of lactitol-based derivatives with a longer half-life in blood for testing against trypanosomal infections.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Trypanosomes
T. cruzi trypomastigotes, the form of the parasite that is liberated from infected mammalian cells, strain CL-Brener (Zingales et al., 1997), were collected from supernatants of infected Vero cell cultures. Vero cells were grown in minimum essential medium (MEM, Sigma) with penicillin and streptomycin (Sigma) and supplemented with 3% FBS-Natocor at 37°C in 5% CO2. Desialylated parasites were collected in BSA (Sigma) using a modified protocol based on Schenkman et al. (1993)
. Subconfluent cultures of Vero cells grown in 75-cm2 flasks were infected with 15 x 106 trypomastigotes and the cells were maintained in 3% FBS-MEM for three days after infection. Cells were washed twice with phosphate buffered saline (PBS) and MEM supplemented with 0.2% BSA, 20 mM HEPES, pH 7.4 (Sigma) (0.2% BSA-MEM). At day 5, supernatants were centrifuged 10 min at 4000 rpm (SS-34 Sorvall) and incubated at 37°C, 3 h to allow motile trypomastigotes to swim up from the pellet. Medium was collected, and parasites were used for cell invasion experiments.
Expression of recombinant TcTS in E. coli
A clone containing the TcTS gene (pTrcTS611/2; Buschiazzo et al., 1997) was used to transform Escherichia coli BL21 (DE3) pLysS (Novagen, Madison, WI). After growth in terrific broth modified (Sigma) containing 100 µg/ml ampicillin (Sigma) at 37°C for 1216 h with constant agitation (250 rpm), the culture was diluted 1:50, and the incubation continued under the same conditions up to A600 1.01.2. Bacteria were induced to overexpress recombinant protein by adding 0.5 mM isopropyl-thio-ß-D-galactopyranoside (Sigma), followed by incubation at 18°C with constant agitation (250 rpm) for 1216 h. Cells were harvested and frozen (80°C) until needed. After thawing, lysis was achieved in the presence of buffer IMAC (20 mM Tris-Cl, pH 8.0, 0.5 M NaCl) plus 0.5% Triton X-100, 1 mM phenylmethylsulphonyl fluoride, 100 µg/ml DNase I, and lysozyme produced by the cells. After 10 min of lysis, the extract viscosity was reduced by six pulses of 30 s ultrasound with a Brandson 450 sonicator. Supernatants were centrifuged at 100,000 x g for 45 min and subjected to iminodiacetic acid metal affinity chromatography (IMAC chelating, Amersham Pharmacia Biotech, Little Chalfont, U.K.) Ni2+-charged. After applying the extract, the column was successively washed with buffer IMAC and 30 mM imidazole in buffer IMAC. The protein was eluted with 100 mM imidazole in the same buffer; dialyzed against 20 mM TrisHCl, pH 8.8, 30 mM NaCl; and further purified by FPLC anionic exchange (MonoQ) applying a linear NaCl elution gradient. The activity peak was pooled and immediately desalted with a fast desalting column (Amersham Pharmacia Biotech). Purified proteins were analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis under reducing conditions, stained with Coomassie blue R250 (Sigma), and quantitated with Kodak 1D 3.0 software using purified BSA as standard.
Preparation of 3-O-ß-D-galactopyranosyl-D-arabinose and 3-O-ß-D-galactopyranosyl-D-arabinitol
2,3,5,6,2',3',4',6'-Octa-O-acetyllactobiononitrile was subjected to the Zemplen degradation method with 2 ml 0.5 M sodium methoxide in methanol affording a mixture of the four 3-O-ß-D-galactopyranosyl-3'-D-arabinoses (p, ßp,
f, ßf ) that was characterized by 13C NMR. This mixture was reduced with NaBH4 to give 3-O-ß-D-galactopyranosyl-D-arabinitol that was also characterized by 13C NMR.
Preparation of 5-[3'-O-ß-D-galactopyranosyl-D-gluco- pentitol-1'-yl]-tetrazole
The 5-[1',2',4',5',2'',3'',4'',6''-octa-O-benzoyl-3'-O-ß-D-galactopyranosyl-D-gluco-pentitol-1'-yl]-tetrazole (115 mg) was dissolved in 0.5 M sodium methoxide in methanol (1 ml), and the solution was kept for 1 h at room temperature. After neutralization by passing through an Amberlite IR-120 (H+) plus resin column (3 ml) the product was eluted with water, lyophilized, and characterized by 1H and 13C NMR spectroscopy.
HPAEC-PAD analysis
Analysis by HPAEC with pulsed amperometric detection (PAD) was performed using a Dionex DX-300 HPLC system equipped with a pulse amperometric detector. The following columns and conditions were used.
Condition 1. A CarboPac PA-100 ion exchange analytical column (4 x 250 mm) equipped with a guard column PA-100 (4 x 50 mm) was used with the following program: 50 mM NaAcO in 100 mM NaOH for 10 min followed by a linear gradient in 80 min from 50 to 500 mM NaAcO in 100 mM NaOH at a flow rate of 1.0 ml/min at room temperature.
Condition 2. A CarboPac PA-100 ion exchange analytical column (4 x 250 mm) equipped with a guard column PA-100 (4 x 50 mm) was used with the following program: a linear gradient over 80 min from 100 to 500 mM NaAcO in 100 mM NaOH at a flow rate of 1.0 ml/min at room temperature.
Condition 3.A CarboPac PA-10 ion exchange analytical column (4 x 250 mm) equipped with a guard column PA-10 (4 x 50 mm) was eluted isocratically with 100 mM NaOH, 50 mM AcONa at a flow rate of 1.0 ml/min at room temperature.
Condition 4. A CarboPac PA-10 ion exchange analytical column (4 x 250 mm) equipped with a guard column PA-10 (4 x 50 mm) was used with the following program: 50 mM AcONa in 100 mM NaOH for 10 min followed by a gradient elution over 20 min from 50 to 100 mM AcONa in 100 mM NaOH at a flow rate of 1.0 ml/min at room temperature.
Condition 5. A CarboPac PA-10 ion exchange analytical column (4 x 250 mm) equipped with a guard column PA-10 (4 x 50 mm) was used isocratically with 60 mM NaOH at a flow rate of 1.0 ml/min at room temperature.
Enzyme kinetics
Reaction mixtures of 20 µl containing 20 mM Tris buffer, pH 7, 30 mM NaCl, 1 mM 3'-sialyllactose as donor and 1 mM acceptor substrate were incubated with 40 ng purified trans-sialidase for different times (0, 15, 30, and 60 min) at 25°C. After incubation, reaction mixtures were diluted with 100 µl deionized water and frozen. Sialylation of acceptors was calculated as the percentage of the sialylated product obtained over the total amount of sialic acid (free or linked to a saccharide). For Km calculations, different concentrations of substrate were incubated for 15 min at 25°C as before. Samples were then diluted 36 times, and 20 µl of each were analyzed by HPAEC. Under the incubation conditions free sialic acid was not detected. The extent of sialylation of substrates was calculated from the decrease in the concentration of 3'-sialyllactose and Km values were obtained graphically by the Lineweaver-Burk method. The rate of reaction was calculated considering the percentage of sialylated product over the total amount of sialic acid (1 mM) and a reaction time of 15 min.
Inhibition of sialylation of N-acetyllactosamine
Reaction mixtures of 20 µl containing buffer 20 mM TrisHCl, pH 7, 30 mM NaCl, 1 mM 3'-sialyllactose, 1 mM N-acetyllactosamine, and different concentrations of inhibitors were incubated with purified trans-sialidase for 30 min at room temperature. Samples were then diluted 36 times with deionized water and analyzed by HPAEC. Inhibition was calculated from the percentages of 3'-sialyl-N-acetyllactosamine obtained with and without inhibitor.
Sialyllactobionic acid as a donor
Sialyllactobionic acid was prepared by incubation of 20 µl of an aqueous solution of fetuin (Sigma F2379) containing 10 mM sialic acid linked to protein, 20 µl 10 mM lactobionic acid, and 3 µl trans-sialidase (60 ng) in a total volume of 200 µl 20 mM Tris, 30 mM NaCl, pH 7, buffer for 1 h at 25°C. Reaction mixture was diluted with 2.3 ml water and applied to a Sephadex-25 P-10 column (Amersham Pharmacia). Elution was performed with water, the first 6 ml were discharged, and the sialyllactobionic acid was eluted with another 6 ml water. After lyophilization, the sialyllactobionic acid was separated by HPAEC and decationized through an Amberlite IR-120 (H+) column that was eluted with water and lyophilized. To confirm that the product contained sialic acid, it was hydrolyzed with 0.1 M HCl for 30 min at 80°C, and the hydrolyzate was analyzed by HPAEC. Purified sialyllactobionic acid was used as sialic acid donor in an incubation containing 1 mM lactose as acceptor and 40 ng trans-sialidase for 1 h at 25°C.
3'-Sialyllactitol and 3'-sialyl-N-acetyllactosamine as donors
3'-Sialyllactitol and 3'-sialyl-N-acetyl-lactosamine were recovered from the TcTS incubations by collecting the corresponding fractions from HPAEC. Solutions were then decationized with an Amberlite IR-120(H+) column (1 ml) eluting with 5 ml water. Different concentrations of the acidic compounds were incubated with 2 µl 10 mM lactose and 40 ng trans-sialidase in a total volume of 20 µl 20 mM TrisHCl (pH 7) buffer, 30 mM NaCl, for 30 min at 25°C. Reaction mixtures were diluted and analyzed by HPAEC.
Inhibition of sialylation of lactose by lactobionic acid
A reaction mixture containing 20 µl lactose (10 mM), 20 µl fetuin (10 mM in sialic acid), and 60 ng trans-sialidase was incubated with or without 20 µl lactobionic acid (10 mM) in a total volume of 200 µl Tris (pH 7) buffer for 1 h at 25°C. After filtration through a Sephadex G-25 P-10 column, the included volume was analyzed by HPAEC-PAD.
Cell invasion experiments
Vero cells were plated in a 24-well plate (105 cells/well) with a sterile 12-mm-diameter glass coverslip in 0.5 ml 10% FBS-MEM and used after 24 h of growth. Before infection, medium was removed and cells were washed twice with PBS; 0.2% BSA-MEM was added in absence or presence of 10 mM lactitol or 10 mM lactose (Sigma) as indicated in each experiment. Trypomastigotes (200 parasites/cell) were incubated for 20 h with cells at 37°C in 5% CO2. Similar results were obtained with 3 h of contact between cells and trypomatigotes, but the percentage of infection was lower. When indicated, trypanosomes were sialylated before infection with 3 µg recombinant trans-sialidase and 1 mM sialyllactose as donor of sialic acid for 30 min. After removing the parasites, the cells were washed with PBS and maintained with 3% FBS-MEM. After 72 h of infection, coverslips were washed twice with PBS; the cells were fixed and stained 5 min with 250 µl of May-Grünwald-Giemsa stain; and then 250 µl water was added. Reagents were removed, and 600 µl Giemsa (1:4 in water) was added in each well. After 5 min, coverslips were washed twice with water and mounted in slides using DPX mountant for histology (Fluka, St. Louis, MO). The number of infected cells was counted in at least 500 cells at 400x. Each experiment was done in triplicate. p-Values were calculated using unpaired two-tailed t-test (p < 0.05). Results were expressed as the mean ± SE of the percentage of infected cells normalized to the values obtained with control trypomastigotes, which were considered 100%.
Sialic acid measurements
Trypomastigotes collected from each of the indicated experiments were stored frozen at 70°C until analysis. Total amount of sialic acid in parasites was determined after hydrolysis in 0.1 M HCl for 1 h at 80°C using the thiobarbituric acid method and HPLC analysis (Powell and Hart, 1986). Results are expressed as pmol of sialic acid per 106 parasites.
![]() |
Acknowledgements |
---|
![]() |
Footnotes |
---|
![]() |
Abbreviations |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Agusti, R., Couto, A.S., Campetella, O.E., Frasch, A.C., and de Lederkremer, R.M. (1997) The trans-sialidase of Trypanosoma cruzi is anchored by two different lipids. Glycobiology, 7, 731735.[Abstract]
Agusti, R., Couto, A.S., Campetella, O., Frasch, A.C., and de Lederkremer, R.M. (1998) Structure of the glycosylphosphatidylinositol-anchor of the trans-sialidase from Trypanosoma cruzi metacyclic trypomastigote forms. Mol. Biochem. Parasitol., 97, 123131.[CrossRef][ISI][Medline]
Amaya, M.F., Buschiazzo, A., Nguyen, T., and Alzari, P.M. (2003) The high resolution structures of free and inhibitor-bound Trypanosoma rangeli sialidase and its comparison with T. cruzi trans-sialidase. J. Mol. Biol., 325, 773784.[CrossRef][ISI][Medline]
Belen Carrillo, M., Gao, W., Herrera, M., Alroy, J., Moore, J.B., Beverley, S.M., and Pereira, M.A. (2000) Heterologous expression of Trypanosoma cruzi trans-sialidase in Leishmania major enhances virulence. Infect. Immun., 68, 27282734.
Buschiazzo, A., Campetella, O., and Frasch, A.C. (1997) Trypanosoma rangeli sialidase: cloning, expression and similarity to T. cruzi trans-sialidase. Glycobiology, 7, 11671173.[Abstract]
Buschiazzo, A., Tavares, G.A., Campetella, O., Spinelli, S., Cremona, M.L., Paris, G., Amaya, M.F., Frasch, A.C., and Alzari, P.M. (2000) Structural basis of sialyltransferase activity in trypanosomal sialidases. EMBO J., 19, 1624.
Buschiazzo, A., Amaya, M.F., Cremona, M.L., Frasch, A.C., and Alzari, P.M. (2002) The crystal structure and mode of action of trans-sialidase, a key enzyme in Trypanosoma cruzi pathogenesis. Mol. Cell, 10, 757768.[ISI][Medline]
Cerecetto, H. and Gonzalez, M. (2002) Chemotherapy of Chagas' disease: status and new developments. Curr. Top. Med. Chem., 2, 11871213.[Medline]
D'Accorso, N.B.D., Zuazo, B.N., and Thiel, I.M.E. (1988) Synthesis and spectra of some octa-O-benzoylaldobiononitriles. Carbohydr. Res., 172, 147155.[CrossRef][ISI]
Frasch, A.C. (2000) Functional diversity in the trans-sialidase and mucin families in Trypanosoma cruzi. Parasitol. Today, 16, 282286.[CrossRef][ISI][Medline]
Fujimura, A.E., Kinoshita, S.S., Pereira-Chioccola, V.L., and Rodrigues, M.M. (2001) DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene. Infect. Immun., 69, 54775486.
Katae, M., Miyahira, Y., Takeda, K., Matsuda, H., Yagita, H., Okumura, K., Takeuchi, T., Kamiyama, T., Ohwada, A., Fukuchi, Y., and Aoki, T. (2002) Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy. Infect. Immun., 70, 48334840.
Kirchhoff, L.V. (2003) Changing epidemiology and approaches to therapy for Chagas disease. Curr. Infect. Dis. Rep., 5, 5965.[Medline]
Leguizamon, M.S., Campetella, O.E., Gonzalez Cappa, S.M., and Frasch, A.C. (1994) Mice infected with Trypanosoma cruzi produce antibodies against the enzymatic domain of trans-sialidase that inhibit its activity. Infect. Immun., 62, 34413446.[Abstract]
Leguizamon, M.S., Mocetti, E., Garcia Rivello, H., Argibay, P., and Campetella, O. (1999) Trans-sialidase from Trypanosoma cruzi induces apoptosis in cells from the immune system in vivo. J. Infect. Dis., 180, 13981402.[CrossRef][ISI][Medline]
Lopez, M., Huynh, C., Andrade, L.O., Pypaert, M., and Andrews, N.W. (2002) Role for sialic acid in the formation of tight lysosome-derived vacuoles during Trypanosoma cruzi invasion. Mol. Biochem. Parasitol., 119, 141145.[CrossRef][ISI][Medline]
Montagna, G., Cremona, M.L., Paris, G., Amaya, M.F., Buschiazzo, A., Alzari, P.M., and Frasch, A.C. (2002) The trans-sialidase from the african trypanosome Trypanosoma brucei. Eur. J. Biochem., 269, 29412950.
Mucci, J., Hidalgo, A., Mocetti, E., Argibay, P.F., Leguizamon, M.S., and Campetella, O. (2002) Thymocyte depletion in Trypanosoma cruzi infection is mediated by trans-sialidase-induced apoptosis on nurse cells complex. Proc. Natl Acad. Sci. USA, 99, 38963901.
Okazaki, S., Suwa, K., Hamasu, Y., and Sumi, N. (1994) Single dose toxicity studies of lactitol (NS-4) in mice and rats. J. Toxicol. Sci., 19(suppl 3), 295299.[Medline]
Othegui, L.C., Fascio, M.L., Martins Alho, M.A., D'Accorso, N.B.D., and Thiel, I.M.E. (1990) Synthesis and spectra for some 5-[octa-O-benzoyl-3'-O-D-hexopyranosyl-D-gluco-pentitol-1'-yl] tetrazoles. Anal. Asoc. Quím. Argentina, 78, 6574.[ISI]
Paris, G., Cremona, M.L., Amaya, M.F., Buschiazzo, A., Giambiagi, S., Frasch, A.C., and Alzari, P.M. (2001) Probing molecular function of trypanosomal sialidases: single point mutations can change substrate specificity and increase hydrolytic activity. Glycobiology, 11, 305311.
Parodi, A.J., Pollevick, G.D., Mautner, M., Buschiazzo, A., Sanchez, D.O., and Frasch, A.C. (1992) Identification of the gene(s) coding for the trans-sialidase of Trypanosoma cruzi. EMBO J., 11, 17051710.[Abstract]
Pitcovsky, T.A., Buscaglia, C.A., Mucci, J., and Campetella, O. (2002) A functional network of intramolecular cross-reacting epitopes delays the elicitation of neutralizing antibodies to Trypanosoma cruzi trans-sialidase. J. Infect. Dis., 186, 397404.[CrossRef][ISI][Medline]
Pontes de Carvalho, L.C., Tomlinson, S., Vandekerckhove, F., Bienen, E.J., Clarkson, A.B., Jiang, M.S., Hart, G.W., and Nussenzweig, V. (1993) Characterization of a novel trans-sialidase of Trypanosoma brucei procyclic trypomastigotes and identification of procyclin as the main sialic acid acceptor. J. Exp. Med., 177, 465474.[Abstract]
Powell, L.D. and Hart, G.W. (1986) Quantitation of picomole levels of N-acetyl- and N-glycolylneuraminic acids by a HPLC-adaptation of the thiobarbituric acid assay. Anal. Biochem., 157, 179185.[ISI][Medline]
Ribeirao, M., Pereira-Chioccola, V.L., Eichinger, D., Rodrigues, M.M., and Schenkman, S. (1997) Temperature differences for trans- glycosylation and hydrolysis reaction reveal an acceptor binding site in the catalytic mechanism of Trypanosoma cruzi trans-sialidase. Glycobiology, 7, 12371246.[Abstract]
Salto, M.L., Gallo-Rodriguez, C., Lima, C., and de Lederkremer, R.M. (2000) Separation of Galfbeta1XGlcNAc and Galpbeta1
XGlcNAc (X = 3, 4, and 6) as the alditols by high-pH anion-exchange chromatography and thin-layer chromatography: characterization of mucins from Trypanosoma cruzi. Anal. Biochem., 279, 7984.[CrossRef][ISI][Medline]
Schenkman, S., Jiang, M.S., Hart, G.W., and Nussenzweig, V. (1991) A novel cell surface trans-sialidase of Trypanosoma cruzi generates a stage-specific epitope required for invasion of mammalian cells. Cell, 65, 11171125.[ISI][Medline]
Schenkman, S., Ferguson, M.A., Heise, N., de Almeida, M.L., Mortara, R.A., and Yoshida, N. (1993) Mucin-like glycoproteins linked to the membrane by glycosylphosphatidylinositol anchor are the major acceptors of sialic acid in a reaction catalyzed by trans-sialidase in metacyclic forms of Trypanosoma cruzi. Mol. Biochem. Parasitol., 59, 293303.[CrossRef][ISI][Medline]
Schenkman, S., Eichinger, D., Pereira, M.E., and Nussenzweig, V. (1994) Structural and functional properties of Trypanosoma trans-sialidase. Annu. Rev. Microbiol., 48, 499523.[CrossRef][ISI][Medline]
Scudder, P., Doom, J.P., Chuenkova, M., Manger, I.D., and Pereira, M.E. (1993) Enzymatic characterization of beta-D-galactoside alpha 2,3-trans-sialidase from Trypanosoma cruzi. J. Biol. Chem., 268, 98869891.
Tiralongo, E., Schrader, S., Lange, H., Lemke, H., Tiralongo, J., and Schauer, R. (2003) Two trans-sialidase forms with different sialic acid transfer and sialidase activities from Trypanosoma congolense. J. Biol. Chem., 278, 2330123310.
Tomlinson, S., Pontes de Carvalho, L.C., Vandekerckhove, F., and Nussenzweig, V. (1994) Role of sialic acid in the resistance of Trypanosoma cruzi trypomastigotes to complement. J. Immunol., 153, 31413147.
Urbina, J.A. and Docampo, R. (2003) Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol., 19, 495501.[CrossRef][ISI][Medline]
Vandekerckhove, F., Schenkman, S., Pontes de Carvalho, L., Tomlinson, S., Kiso, M., Yoshida, M., Hasegawa, A., and Nussenzweig, V. (1992) Substrate specificity of the Trypanosoma cruzi trans-sialidase. Glycobiology, 2, 541548.[Abstract]
Watts, A.G., Damager, I., Amaya, M.L., Buschiazzo, A., Alzari, P., Frasch, A.C., and Withers, S.G. (2003) Trypanosoma cruzi trans-sialidase operates through a covalent sialyl-enzyme intermediate: tyrosine is the catalytic nucleophile. J. Am. Chem. Soc., 125, 75327533.[CrossRef][ISI][Medline]
Wizel, B., Garg, N., and Tarleton, R.L. (1998) Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection. Infect. Immun., 66, 50735081.
Zingales, B., Pereira, M.E., Almeida, K.A., Umezawa, E.S., Nehme, N.S., Oliveira, R.P., Macedo, A., and Souto, R.P. (1997) Biological parameters and molecular markers of clone CL Brenerthe reference organism of the Trypanosoma cruzi genome project. Mem. Inst. Oswaldo Cruz, 92, 811814.[ISI][Medline]